达格列净治疗急性心肌梗死合并应激性高血糖的效果

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract

Objective To investigate the effect of Dapagliflozin in the treatment of acute myocardial infarction with stress hyperglycemia.Methods From January 2017 to December 2019, 66 patients with acute myocardial infarction and stress hyperglycemia who were hospitalized in the department of internal medicine cardiovascular of our hospital were selected as the research objects.They were divided into group D (30 cases) and group I (36 cases) according to the random number table method.Patients in group D were given Dapagliflozin, and group I was given Insulin.The blood glucose, cardiac function and other indicators were compared between the two groups.Results Fasting blood glucose(FBG) and blood glucose (2h PBG) at 1 and 6 weeks after treatment were both lower in the two groups than those before treatment, with statistically significant differences (P<0.05).After 1 week of treatment, the levels of FBG and 2h PBG in group D were lower than those in group I, with statistically significant differences (P<0.05).After 6 weeks of treatment, the left ventricular ejection fraction (LVEF) of group D was higher than that of group I, and the body mass index (BMI) was lower than that of group I, with statistically significant differences (P<0.05).The incidence of hypoglycemia between the two groups was not statistically significant (P>0.05).Conclusion Dapagliflozin is effective in treating patients with acute myocardial infarction combined with stress hyperglycemia, and can effectively improve cardiac function with good safety.

Key words： Acute myocardial infarction Stress hyperglycemia Dapagliflozin

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I20/65

[1]	Zein AF，Nasution SA，Purnamasari D，et al.The influence of hyperglycemia at admission on in-hospital arrhythmia patients with acute coronary sundrome[J].Acta Med Indones，2015，47（4）：291-296.
[2]	Terlecki M，Bednarek A，Bednarek A，et al.The risk of diabetes development in long-term observation of patients with acute hyperglycaemia during myocardial infarction[J].Kardiol Pol，2015，73（8）：606-612.
[3]	Iwakura K.Stress hyperglycemia and microvascular obstruction affter acute myocardial infarction[J].J Cardiol，2015，65（4）：270-271.
[4]	Anand SS，Dagenais GR，Mohan V，et al.Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glcaemic and dysglycaemic men and women：the EpiDREAM cohort study[J].Eur J Prev Cardiol，2012，19（4）：755-764.
[5]	刘戬，潘宜智，李广镰，等.血糖对急性心肌梗死患者冠脉内介入术后近期预后的影响[J].江西医学院院报，2007，47（3）：55-58.
[6]	Van der Horst IC，Nijsten MW，Vogelzang M，et al.Persistent hyperglycemia is an independent predictor of outcome in acute myocardial infarction[J].Cardiobasc Diabetol，2007，6：2.
[7]	Worthley MI，Holmes AS，W illoughby SR，et al.The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes mediation by superoxide production，resolution with inetnsive insulin administration[J].J Am Coil Cardiol，2007，49（3）：304-310.
[9]	Saleem F.Dapagliflozin：cardiovascular safety and benefits in type2 diabetes mellitus[J].Cureus，2017，9（10）：e1751.
[10]	陈阳，徐兆龙，刘仁光.心肌梗死第三次全球统一定义[J].辽宁医学院学报，2013，34（1）：1-5.
[11]	娄国忠，夏志荣.急性心肌梗死与应激性高血糖关系探讨[J].心血管病防治，2004，6（4）：32-33.
[8]	Davies MJ，Dálessio DA，Fradkin J，et al.Management of hyperglycemia in type 2 diabetes，2018.A consensus report by the American Diabetes Association （ADA） and the European Association for the Study of Diabetes （EASD）[J].Diabetes Care，2018，41（12）：2669-2701.
[12]	葛均波，徐永健.内科学[M].8版.北京：人民卫生出版社，2014：733-752.
[13]	Yang W，Ji L，Zhou Z，et al.Efficacy and safety of dapagliflozin in Asian patients：A pooled analysis[J].J Diabetes，2017，9（8）：787-799.
[14]	Sha S，Polidori D，Heise T，et al.Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus[J].Diabetes Obes Metab，2014，16（11）：1087-1095.
[15]	Ferrannini G，Hach T，Crowe S，et al.Energy Balance After Sodium-Glucose Cotranspoter 2 Inhibition[J].Diabetes Care，2015，38（9）：1730-1735.
[16]	Imprialos KP，Sarafidis AI.Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease：a valuable effect of a novel antidiabetic class?[J].J Hypertens，2015，33（11）：2185-2197.
[17]	Li T，Zhang Z，Kolwicz SC，et al.Defective branched-chain amino acid catabolism disrupts glucose metabolism and sensitizes the heart to ischemia-reperfusion Injury[J].Cell Metab，2017，25（2）：374-385.